Insulin promotes macrophage foam cell formation: Potential implications in diabetes-related atherosclerosis

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1171-1180

  Park, Young M ^a,b   Kashyap, Sangeeta R ^b   Major, Jennifer A ^b   Silverstein, Roy L ^b,c,d  

^a Ewha Womans University School of Medicine   (South Korea)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

ABCA1; atherosclerosis; CD36; foam cell; insulin; macrophage

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; APOLIPOPROTEIN A1; CD36 ANTIGEN; CHOLESTEROL; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOWN REGULATION; FOAM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ADIPONECTIN; ANTIGENS, CD36; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; DIABETIC ANGIOPATHIES; FOAM CELLS; HUMANS; INSULIN; LIPOPROTEINS, LDL; MACROPHAGES; SCAVENGER RECEPTORS, CLASS A;

EID: 84864481830     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.74     Document Type: Article

References (65)

1. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
2. Marray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors; Global Burden of Disease Study. Lancet 1997;349: 1436-1442.
3. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979;2:120-126.
4. Pyö rälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Dev 1987;3:463-524.
5. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229-234.
6. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
7. Rutter MK, Meigs JB, Sullivan LM, et al. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005;54:3252-3257.
8. Hanley AJ, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25: 1177-1184.
9. DeFronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler suppl 2006;7:11-15.
10. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Cerona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.
11. Reddy KJ, Singh M, Bangit JR, et al. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. J Cardiovasc Med 2010;11:633-647.
12. Pyö rälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-141.
13. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
14. Ducimetiere D, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in middle-aged population. Diabetologia 1980; 19:205-210.
15. Pyö rälä K, Savolainen E, Kankola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1 2 year follow-up of the Helsinki Policemen Study population. Acta Med Scand 1985;701(suppl 1):38-52.
16. Eschwege E, Richard JL, Thibault N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985;15(suppl):41-46.
17. Haffner SM, Stern MP, Hazuda HP, et al. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1986;315:220-224.
18. Welin L, Eriksson H, Larsson B, et al. Hyperinsulinemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 1992;35:766-770.
19. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol 1994;140:857-869.
20. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002;8:1235-1242.
21. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008;79: 360-376.
22. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-1056.
23. de Winther MP, Hofker MH. Scavenging new insights into atherogenesis. J Clin Invest 2000;105:1039-1041.
24. Terpstra V, Kondratenko N, Steinberg D. Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated lowdensity lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells. Proc Natl Acad Sci USA 1997;94:8127-8131.
25. Van Eck M, Pennings M, Hoekstra M, et al. Scavenger receptor B1 and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005;16:307-315.
26. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-58.
27. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009;296:E22-E36.
28. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor g agonists. J Biol Chem 2006;281:2654-2660.
29. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
30. Hotta K, Funahashi T, bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
31. Wang C, Mao X, Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 2007;282:7991-7996.
32. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
33. Furukawa K, Hori M, Ouchi N, et al. Adiponectin down-regulates acylcoenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004; 317:831-836.
34. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999;103:1547-1560.
35. Rye KA, Garrety KH, Barter PJ. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J Lipid Res 1992;33:215-224.
36. Rahaman SO, Lennon DJ, Febbraio M, et al. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006;4:211-221.
37. Robinet P, Wang Z, Hazen SL, et al. A simple and sensitive enzymatic method for cholesterol quantification in macrophages and foam cells. J Lipid Res 2010;51:3364-3369.
38. Liang CP, Han S, Okamoto H, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;113:764-773.
39. Han J, Hajjar DP, Febbraio M, et al. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 1997;272:21654-21659.
40. Nagy L, Tontonoz P, Alvarez J, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell 1998;93:229-240.
41. Sugano R, Yamamura T, Harada-Shiba M, et al. Uptake of oxidized lowdensity lipoprotein in a THP-1 cell line lacking scavenger receptor A. Atherosclerosis 2001;158:351-357.
42. Tang CK, Yi GH, Yang JH, et al. Oxidized LDL upregulated ATP binding cassette transporter-1 in THP-1 macrophages. Acta Pharmacol Sin 2004;25:581-586.
43. Zhao Y, Van Berkel TJ, Van Eck M. Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Curr Opin Lipidol 2010;21:441-453.
44. Janabi M, Yamashita S, Hirano K, et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000;20:1953-1960.
45. Stout RW, Vallance-Owen J. Insulin and atheroma. Lancet 1969;i: 1078-1080.
46. Ronnemaa T, Laakso M, Pyorala K, et al. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 1991; 11:80-90.
47. Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Horm Metab Res 1985;15(Suppl):46-51.
48. Uusitupa MIJ, Niskanen LK, Siitonen O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulindependent diabetic and nondiabetic subjects. Circulation 1990;82:27-36.
49. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002;16:401-415.
50. Welham MJ, Bone H, Levings M, et al. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohematopoietic cells. J Biol Chem 1997;272:1377-1381.
51. Malide D, Davies-Hill TM, Levine M, et al. Distinct localization of GLUT-1,-3, and-5 in human monocyte-derived macrophages: effects of cell activation. Am J Physiol 1998;274:E516-E526.
52. Smith J, Su X, El-Maghrabi R, et al. Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem 2008;283:13578-13585.
53. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106:2767-2770.
54. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
55. Tian L, Luo N, Klein RL, et al. Adiponectin reduces lipid accumulation in macrophage foam cells. Atheroscler 2009;202:152-161.
56. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999;103:1547-1560.
57. Goldstein JL, Ho YK, Basu SK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Nat Acad Sci 1979;76:333-337.
58. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
59. Miller YI, Viriyakosol S, Worrall DS, et al. Toll-like receptor 4-dependent and-independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005;25:1213-1219.
60. Ghanim H, Mohanty P, Deopurkar R, et al. Acute modulation of toll-like receptors by insulin. Diabetes Care 2008;31:1827-1831.
61. Iwasaki Y, Nishiyama M, Taguchi T, et al. Insulin exhibits short-term anti-inflammatory but long-term proinflammatory effects in vitro. Mol Cell Endocrinol 2009;298:25-32.
62. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153-6160.
63. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23 000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-765.
64. Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Diab Vasc Dis Res 2009;6:223-230.
65. Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008;31(Suppl 2):S262-S268.